Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Key facts

Study ID

NCT00005028

Run by

University of Maryland, Baltimore

People needed

46

Starts

2000-05-01

Expected to finish

2006-07-01

Last updated by the study team

2019-11-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Greater Baltimore Medical Center and Cancer Center — Baltimore, Maryland, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Wellspan Health - York Cancer Center — York, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.